Fauci orchestrated fraudulent studies, and then pressured US Food and Drug Administration (FDA) regulators into approving a deadly chemotherapy treatment he had good reason to know was worthless against AIDS. The Real Anthony Fauci reveals how “America’s Doctor” launched his career during the early AIDS crisis by partnering with pharmaceutical companies to sabotage safe and effective off-patent therapeutic treatments for AIDS. and that will alarm every American-Democrat or Republican-who cares about democracy, our Constitution, and the future of our children’s health. unearthed a shocking story that obliterates media spin on Dr. Fauci uses the financial clout at his disposal to wield extraordinary influence over hospitals, universities, journals, and thousands of influential doctors and scientists-whose careers and institutions he has the power to ruin, advance, or reward.ĭuring more than a year of painstaking and meticulous research, Robert F.

Anthony Fauci dispenses $6.1 billion in annual taxpayer-provided funding for scientific research, allowing him to dictate the subject, content, and outcome of scientific health research across the globe. He is anything but.Īs director of the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Pharma-funded mainstream media has convinced millions of Americans that Dr. Price Action: BNED shares traded lower by 21.2% at $6.98 on the last check Tuesday.#1 on AMAZON, and a NEW YORK TIMES, WALL STREET JOURNAL, USA TODAY and PUBLISHERS WEEKLY NATIONAL BESTSELLER.The company expects non-GAAP adjusted EBITDA to approach annual pre-COVID levels in FY23.Outlook: Barnes & Noble Education expects to generate positive non-GAAP Adjusted EBITDA in FY22.Barnes & Noble Education held $23.5 million in cash and equivalents as of October 30, 2021.

Adjusted EBITDA of $39 million rose 59.2% from last year.

The operating margin was 4%, with the operating income increasing 265% Y/Y to $24.6 million.

Gross profit rose 26.3% Y/Y to $145.6 million with a margin of 23.2%.

Comparable textbook sales remained essentially flat, compared to a 19% decline a year ago, as enrollment declines were mitigated by the growth of First Day offerings.

Retail segment gross comparable store sales increased 13.2%, and retail sales rose 5.6%.

Barnes & Noble Education Inc (NYSE: BNED) reported second-quarter FY22 sales growth of 5.3% year-on-year, to $626.98 million, missing the analyst consensus of $663.30 million.

One up on wall street barnes and noble